FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: The FcRn blocker efgartigimod has recently been approved by the U.S. Food and Drug Administration for the treatment of anti-acetylcholine receptor antibody positive myasthenia gravis and is currently under investigation in CIDP.